Jr. Murren et al., A PHASE-II TRIAL OF MITOMYCIN-C, 5-FLUOROURACIL AND RADIATION-THERAPYIN THE TREATMENT OF UNRESECTABLE NONSMALL CELL LUNG-CANCER, Oncology research, 5(2), 1993, pp. 53-57
We conducted a study evaluating the efficacy of simultaneous administr
ation of 5-fluorouracil. mitomycin C, and X-irradiation in unresectabl
e Stage III non-small cell lung cancer. Radiation was delivered in a s
plit course to a total of 55 Gy. In the first course, radiation was ad
ministered daily in 250 cGy fractions for 12 treatments. Following a t
wo week rest, an additional 10 treatments of 200 cGy fractions were de
livered. Chemotherapy consisted of 10 mg/M2 of Mitomycin C on day 1, a
nd 1000 mg/M2 per day of 5 -fluorouracil by continuous infusion on day
s 1 through 5 and 29 through 33. Twenty-one enrolled patients were eva
luable. The overall response rate was 52% (95% confidence intervals 31
-73%), with a median duration of response of 42 weeks. There were 5 co
mplete responders (24%) and four of these patients remain disease-free
with follow-up between 24-54 months. The median survival time for all
patients was 59 weeks. For the complete responders the median surviva
l time has not yet been reached, but is in excess of 42 months. Toxici
ty consisted of moderate stomatitis and myclosuppression. The sustaine
d remissions obtained by 4 of 21 patients (18%) treated with concurren
t mitomycin C, 5-fluorouracil and x-irradiation are encouraging and de
serve further study